JP2021080212A - Cell proliferation promoter, mmp-2 inhibitor, topical skin preparation, pharmaceutical and internal preparation - Google Patents
Cell proliferation promoter, mmp-2 inhibitor, topical skin preparation, pharmaceutical and internal preparation Download PDFInfo
- Publication number
- JP2021080212A JP2021080212A JP2019209598A JP2019209598A JP2021080212A JP 2021080212 A JP2021080212 A JP 2021080212A JP 2019209598 A JP2019209598 A JP 2019209598A JP 2019209598 A JP2019209598 A JP 2019209598A JP 2021080212 A JP2021080212 A JP 2021080212A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- mmp
- agrimonia pilosa
- cell proliferation
- agrimonia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 230000004663 cell proliferation Effects 0.000 title claims abstract description 12
- 239000003112 inhibitor Substances 0.000 title claims description 3
- 230000000699 topical effect Effects 0.000 title abstract 2
- 241001278836 Agrimonia pilosa Species 0.000 claims abstract description 50
- 235000000641 Agrimonia pilosa Nutrition 0.000 claims abstract description 50
- 239000000284 extract Substances 0.000 claims abstract description 40
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims abstract description 23
- 101710151806 72 kDa type IV collagenase Proteins 0.000 claims abstract description 23
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 230000037303 wrinkles Effects 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 229940127557 pharmaceutical product Drugs 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 16
- 230000001737 promoting effect Effects 0.000 abstract description 9
- 239000002537 cosmetic Substances 0.000 abstract description 8
- 206010028980 Neoplasm Diseases 0.000 abstract description 7
- 201000011510 cancer Diseases 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 7
- 230000032683 aging Effects 0.000 abstract description 6
- 238000011282 treatment Methods 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000009759 skin aging Effects 0.000 abstract description 2
- 206010011953 Decreased activity Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 24
- 239000004615 ingredient Substances 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 239000000203 mixture Substances 0.000 description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 239000000469 ethanolic extract Substances 0.000 description 14
- 238000000605 extraction Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 229940058015 1,3-butylene glycol Drugs 0.000 description 12
- 235000019437 butane-1,3-diol Nutrition 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- -1 pH regulators Substances 0.000 description 11
- 239000008213 purified water Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 239000003205 fragrance Substances 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000007665 sagging Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 241001092084 Agrimonia Species 0.000 description 4
- 235000016993 Agrimonia Nutrition 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 210000001339 epidermal cell Anatomy 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 241000220221 Rosales Species 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 108010028309 kalinin Proteins 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、細胞増殖促進剤、MMP−2阻害剤、皮膚外用剤、医薬品及び内用剤に関する。 The present invention relates to cell proliferation promoters, MMP-2 inhibitors, external preparations for skin, pharmaceuticals and internal preparations.
加齢と共に表皮細胞の増殖・***能は低下し、表皮層自体は薄くなる(非特許文献1)。生体因子であるEpidermal Growth Factor(EGF/上皮細胞成長因子)や女性ホルモン(エストロゲン)は皮膚の表皮細胞増殖に働きかけるが、加齢と共にその分泌は低下する。このような加齢による表皮細胞代謝機能の低下は、皮膚のターンオーバー速度を遅らせ、肌荒れや皮膚の老化の原因となる。また、角層表面から剥がれ落ちる角層細胞が滞留することで、表皮内メラニンの***がスムーズに行われなくなり、色素沈着や肌のくすみの原因となる。さらに表皮の創傷治癒が遅くなること等も知られている。これらの現象の進行を防止あるいは改善するために、表皮細胞の増殖を促進させる成分の探索や、多くの皮膚外用剤の提案がなされてきた。 With aging, the proliferation and division ability of epidermal cells decreases, and the epidermal layer itself becomes thin (Non-Patent Document 1). The biological factors Epidermal Growth Factor (EGF / epidermal growth factor) and female hormone (estrogen) act on the proliferation of epidermal cells in the skin, but their secretion decreases with aging. Such a decrease in epidermal cell metabolic function due to aging slows down the turnover rate of the skin and causes rough skin and aging of the skin. In addition, the retention of stratum corneum cells that peel off from the surface of the stratum corneum prevents smooth excretion of melanin in the epidermis, which causes pigmentation and dullness of the skin. It is also known that wound healing of the epidermis is delayed. In order to prevent or improve the progression of these phenomena, the search for components that promote the proliferation of epidermal cells and the proposal of many external preparations for skin have been made.
マトリックスメタロプロテアーゼ(以下MMPとする)に属するゼラチナーゼ(MMP−2)は、線維芽細胞や内皮細胞、ガン細胞等が産生する酵素であり、コラーゲン、ゼラチン、エラスチン(動脈、腱、皮膚など弾性組織の特殊成分をなす構造タンパク質)等の基質や基底膜の主要構成成分であるラミニン5などを分解する。その発現及び活性は、紫外線の照射により大きく増加し、紫外線による基底膜成分の減少、基底膜の構造変化の原因となり、皮膚におけるシワやたるみの形成等の大きな要因となることが明らかとなっている(非特許文献2)。従って、ゼラチナーゼに対して阻害活性を有する物質は、皮膚におけるシワやたるみの予防だけでなく、ガン組織における血管新生やガンの転移を抑制する効果が期待され、ガン疾患の予防、治療に有用であると考えられる。さらに、MMP−2は、潰瘍形成、慢性関節リュウマチ、骨粗鬆症、歯周炎等の種々の病態での細胞外基質の分解に関与していることが報告されている。よって、MMP−2の阻害活性を有すれば、ガンの転移、潰瘍形成、慢性関節リュウマチ、骨粗鬆症、歯周炎等、MMP−2の亢進が原因で起こる各種疾患の治療及び改善に有用である。 Zelatinase (MMP-2), which belongs to matrix metalloproteinase (hereinafter referred to as MMP), is an enzyme produced by fibroblasts, endothelial cells, cancer cells, etc., and is an elastic tissue such as collagen, gelatin, and elastin (arteries, tendons, skin, etc.). Decomposes substrates such as (structural proteins that form a special component of) and laminin 5, which is a major constituent of the basement membrane. It has been clarified that its expression and activity are greatly increased by irradiation with ultraviolet rays, cause a decrease in basement membrane components due to ultraviolet rays, cause structural changes in the basement membrane, and become a major factor such as formation of wrinkles and sagging in the skin. (Non-Patent Document 2). Therefore, a substance having an inhibitory activity on gelatinase is expected to have an effect of suppressing angiogenesis and cancer metastasis in cancer tissue as well as preventing wrinkles and sagging in the skin, and is useful for prevention and treatment of cancer diseases. It is believed that there is. Furthermore, MMP-2 has been reported to be involved in the degradation of extracellular matrix in various pathological conditions such as ulceration, rheumatoid arthritis, osteoporosis, and periodontitis. Therefore, if it has an inhibitory activity of MMP-2, it is useful for treating and ameliorating various diseases caused by an increase in MMP-2, such as cancer metastasis, ulceration, rheumatoid arthritis, osteoporosis, and periodontitis. ..
バラ目バラ科キンミズヒキ属のキンミズヒキ(Agrimonia pilosa)は、その全草の抽出物が、チロシナーゼ活性阻害作用や活性酸素阻害作用を有し、美白及び老化防止化粧料に適用されること(特許文献1)や、メラニン生成抑制作用やMMP−1活性阻害作用、コラーゲン産生促進作用を有し、皮膚化粧料に適用されること(特許文献2)、ドーパオキシダーゼ活性抑制作用を有し美白剤に適用されること(特許文献3)が知られている。しかしながら、これらのキンミズヒキが、細胞増殖促進作用及びMMP−2阻害作用を有することは知られていなかった。 Agrimonia pilosa, which belongs to the genus Agrimonia of the Rosales family, has a tyrosinase activity-inhibiting effect and an active oxygen-inhibiting effect, and is applied to whitening and antiaging cosmetics (Patent Document 1). ), It has melanin production inhibitory action, MMP-1 activity inhibitory action, collagen production promoting action, and is applied to skin cosmetics (Patent Document 2), and it has dopaoxidase activity inhibitory action and is applied to whitening agents. (Patent Document 3) is known. However, it has not been known that these Agrimonia pilosa have cell proliferation promoting action and MMP-2 inhibitory action.
安全で安定性に優れ、細胞増殖促進作用及びMMP−2阻害作用に優れた素材が望まれているが、未だ十分満足し得るものが提供されていないのが現状である。 Materials that are safe, have excellent stability, and have excellent cell proliferation promoting action and MMP-2 inhibitory action are desired, but at present, materials that are sufficiently satisfactory have not been provided.
このような事情により、本発明者らは鋭意検討した結果、キンミズヒキの抽出物が優れた細胞増殖促進作用及びMMP−2阻害作用を持ち、安定性においても優れていることを見出した。さらに、その抽出物を含有する外用剤又は内用剤が、安全で安定であり、細胞増殖促進作用及びMMP−2阻害作用に優れており、多機能性美容・健康用素材・医薬品と成り得ることを見いだし、本発明を完成するに至った。 Under these circumstances, the present inventors have diligently studied and found that the extract of Agrimonia pilosa has excellent cell proliferation promoting action and MMP-2 inhibitory action, and is also excellent in stability. Furthermore, the external or internal preparation containing the extract is safe and stable, has excellent cell proliferation promoting action and MMP-2 inhibitory action, and can be a multifunctional beauty / health material / pharmaceutical product. We found that and came to complete the present invention.
本発明に用いるキンミズヒキは、バラ目バラ科キンミズヒキ属の植物で、日本から東ヨーロッパにかけて広く分布している多年草である。日本では、本州、四国、九州などの林や原野、路傍などに生息している。草丈は1m程にまで伸び、表面には全体的に長毛が密生している。夏から秋にかけ、長く伸びた茎の上部に、黄色の小さな花を穂状につける。この黄色い小花を細長く穂のように咲かせる姿を「金色の水引」に見立てて、「キンミズヒキ」の名がついたと言われている。生薬名は、「仙鶴草」もしくは「龍牙草」という。 Agrimonia pilosa used in the present invention is a plant belonging to the genus Agrimonia of the Rosales family, and is a perennial plant widely distributed from Japan to Eastern Europe. In Japan, it inhabits forests, wilderness, and roadsides in Honshu, Shikoku, and Kyushu. The plant height grows to about 1 m, and long hairs are densely grown on the surface. From summer to autumn, small yellow flowers are sprouted on the top of the long stems. It is said that the name "Kinmizuhiki" was given to the appearance of these yellow florets blooming like elongated spikes, as if they were "golden mizuhiki". The crude drug name is "Senzuru grass" or "Ryuga grass".
本発明におけるキンミズヒキの抽出物とは、バラ目バラ科キンミズヒキ属のキンミズヒキ(学名:Agrimonia pilosa)が用いられ、部位としては、花、実、種子、葉、茎、根等の植物体の一部又は全草から抽出したものである。その抽出方法は特に限定されず、例えば、加熱抽出したものであってもよいし、常温抽出したものであってもよい。また、抽出には、植物体をそのまま使用してもよく、乾燥、粉砕、細切等の処理を行ってもよい。 As the extract of Agrimonia in the present invention, Agrimonia pilosa (scientific name: Agrimonia pilosa) of the genus Agrimonia of the Rosales family is used, and the site is a part of a plant such as flowers, fruits, seeds, leaves, stems and roots. Or it is extracted from whole plant. The extraction method is not particularly limited, and for example, it may be heat-extracted or room-temperature extracted. In addition, the plant body may be used as it is for extraction, or may be subjected to treatments such as drying, crushing, and shredding.
抽出方法は、特に限定されないが、水もしくは熱水、又は水と有機溶媒の混合溶媒を用い、撹拌又はカラム抽出する方法等により行うことができる。抽出溶媒としては、例えば、水、低級アルコール類(メタノール、エタノール、1−プロパノール、2−プロパノール、1−ブタノール、2−ブタノール等)、液状多価アルコール類(1,3−ブチレングリコール、プロピレングリコール、グリセリン等)、ケトン類(アセトン、メチルエチルケトン等)、アセトニトリル、エステル類(酢酸エチル、酢酸ブチル等)、炭化水素類(ヘキサン、ヘプタン、流動パラフィン等)、エーテル類(ジエチルエーテル、テトラヒドロフラン、プロピルエーテル等)が挙げられる。好ましくは、水、低級アルコール及び液状多価アルコール等の極性溶媒が良く、特に好ましくは、水、エタノール、1,3−ブチレングリコール及びプロピレングリコールがよい。これらの溶媒は一種でも二種以上を混合して用いてもよい。特に好ましい抽出溶媒としては、水、又は水−エタノール系の混合極性溶媒が挙げられる。溶媒の使用量については、特に限定はなく、例えばキンミズヒキの全草(乾燥重量)に対し、10倍以上、好ましくは20倍以上であればよいが、抽出後に濃縮を行ったり、単離したりする場合の操作の便宜上100倍以下であることが好ましい。また、抽出温度や時間は、用いる溶媒の種類や抽出時の圧力等によって適宜選択できる。 The extraction method is not particularly limited, but can be carried out by a method of stirring or column extraction using water or hot water, or a mixed solvent of water and an organic solvent. Examples of the extraction solvent include water, lower alcohols (methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, etc.) and liquid polyhydric alcohols (1,3-butylene glycol, propylene glycol, etc.). , Glycerin, etc.), Ketones (acetone, methyl ethyl ketone, etc.), acetonitrile, esters (ethyl acetate, butyl acetate, etc.), hydrocarbons (hexane, heptane, liquid paraffin, etc.), ethers (diethyl ether, tetrahydrofuran, propyl ether, etc.) Etc.). Polar solvents such as water, lower alcohols and liquid polyhydric alcohols are preferred, and water, ethanol, 1,3-butylene glycol and propylene glycol are particularly preferred. These solvents may be used alone or in admixture of two or more. Particularly preferable extraction solvents include water and water-ethanol mixed polar solvents. The amount of the solvent used is not particularly limited, and may be, for example, 10 times or more, preferably 20 times or more, based on the whole plant (dry weight) of Agrimonia pilosa, but may be concentrated or isolated after extraction. It is preferably 100 times or less for convenience of operation in the case. The extraction temperature and time can be appropriately selected depending on the type of solvent used, the pressure at the time of extraction, and the like.
上記抽出物は、抽出した溶液のまま用いてもよいが、必要に応じて、本発明の効果を奏する範囲で、濃縮(減圧濃縮、膜濃縮等による濃縮)、希釈、濾過、活性炭等による脱色、脱臭、エタノール沈殿等の処理を行ってから用いてもよい。さらには、抽出した溶液を濃縮乾固、噴霧乾燥、凍結乾燥等の処理を行い、乾燥物として用いてもよい。 The above extract may be used as it is in the extracted solution, but if necessary, concentration (concentration by vacuum concentration, membrane concentration, etc.), dilution, filtration, decolorization with activated carbon, etc. is performed within the range in which the effect of the present invention is exhibited. , Deodorization, ethanol precipitation, etc. may be performed before use. Further, the extracted solution may be subjected to treatments such as concentrated drying, spray drying, freeze drying and the like, and used as a dried product.
本発明は、上記抽出物をそのまま使用しても良く、抽出物の効果を損なわない範囲内で、化粧品、医薬部外品、医薬品及び食品等に用いられる成分である油脂類、ロウ類、炭化水素類、脂肪酸類、アルコール類、エステル類、界面活性剤、金属石鹸、pH調整剤、防腐剤、香料、保湿剤、粉体、紫外線吸収剤、増粘剤、色素、酸化防止剤、美白剤、キレート剤、賦形剤、皮膜剤、甘味料、酸味料等の成分が含有されていてもよい。 In the present invention, the above extract may be used as it is, and oils and fats, waxes, and carbonized components used in cosmetics, non-pharmaceutical products, pharmaceuticals, foods, etc., as long as the effect of the extract is not impaired. Hydrogens, fatty acids, alcohols, esters, surfactants, metal soaps, pH regulators, preservatives, fragrances, moisturizers, powders, UV absorbers, thickeners, pigments, antioxidants, whitening agents , Chelating agents, excipients, filming agents, sweeteners, acidity agents and the like may be contained.
本発明は、化粧品、医薬部外品、医薬品、食品のいずれにも用いることができ、その剤形としては、例えば、化粧水、クリーム、乳液、ゲル剤、エアゾール剤、エッセンス、パック、洗浄剤、浴用剤、ファンデーション、打粉、口紅、軟膏、パップ剤、錠菓、カプセル剤、チョコレート、ガム、飴、飲料、散剤、顆粒剤、錠剤、糖衣錠剤、カプセル剤、シロップ剤、丸剤、懸濁剤、液剤、乳剤、坐剤、注射用溶液等が挙げられる。 The present invention can be used for any of cosmetics, non-pharmaceutical products, pharmaceuticals, and foods, and the dosage forms thereof include, for example, cosmetics, creams, emulsions, gels, aerosols, essences, packs, and cleaning agents. , Baths, foundations, dusting, lipsticks, ointments, poultices, tablets, capsules, chocolates, gums, candy, beverages, powders, granules, tablets, sugar-coated tablets, capsules, syrups, pills, suspensions Examples include agents, solutions, emulsions, suppositories, solutions for injection and the like.
外用の場合、本発明に用いる上記抽出物の含有量は、固形物に換算して0.0001重量%以上が好ましく、0.001〜10重量%がより好ましい。さらに、0.01〜5重量%が最も好ましい。0.0001重量%未満では十分な効果は望みにくい。10重量%を越えると、効果の増強は認められにくく不経済である。 In the case of external use, the content of the extract used in the present invention is preferably 0.0001% by weight or more, more preferably 0.001 to 10% by weight in terms of solid matter. Further, 0.01 to 5% by weight is most preferable. If it is less than 0.0001% by weight, it is difficult to expect a sufficient effect. If it exceeds 10% by weight, the enhancement of the effect is hardly recognized and it is uneconomical.
内用の場合、摂取量は年齢、体重、症状、治療効果、投与方法、処理時間等により異なる。通常、成人1人当たりの1日の摂取量としては、5mg以上が好ましく、10mg〜5gがより好ましい。さらに、20mg〜2gが最も好ましい。 For internal use, the intake varies depending on age, body weight, symptoms, therapeutic effect, administration method, treatment time, and the like. Usually, the daily intake per adult is preferably 5 mg or more, and more preferably 10 mg to 5 g. Further, 20 mg to 2 g is most preferable.
次に本発明を詳細に説明するため、実施例として本発明に用いる抽出物の製造例、実験例及び処方例を挙げるが、本発明はこれに限定されるものではない。製造例に示す%とは重量%を、処方例に示す含有量の部とは重量部を示す。 Next, in order to explain the present invention in detail, examples of production, experiment, and formulation of the extract used in the present invention will be given as examples, but the present invention is not limited thereto. The% shown in the production example means% by weight, and the content part shown in the formulation example means a weight part.
キンミズヒキの抽出物の製造例
キンミズヒキの抽出物を以下のとおり製造した。製造例1〜4において抽出材料にはキンミズヒキの全草を用いた。
Example of production of Agrimonia pilosa extract An extract of Agrimonia pilosa was produced as follows. In Production Examples 1 to 4, the whole plant of Agrimonia pilosa was used as the extraction material.
(製造例1)キンミズヒキの熱水抽出物の調製
キンミズヒキの乾燥物10gに200mLの水を加え、95〜100℃で2時間抽出した。得られた抽出液を濾過し、その濾液を濃縮し、凍結乾燥してキンミズヒキの熱水抽出物を0.9g得た。
(Production Example 1) Preparation of hot water extract of Agrimonia pilosa 200 mL of water was added to 10 g of a dried product of Agrimonia pilosa, and the mixture was extracted at 95 to 100 ° C. for 2 hours. The obtained extract was filtered, the filtrate was concentrated, and freeze-dried to obtain 0.9 g of a hot water extract of Agrimonia pilosa.
(製造例2)キンミズヒキの50%エタノール抽出物の調製
キンミズヒキの乾燥物10gを200mLの50%エタノール水溶液に室温で7日間浸漬し抽出を行った。得られた抽出液を濾過した後、エバポレーターで濃縮乾固してキンミズヒキの50%エタノール抽出物を1.0g得た。
(Production Example 2) Preparation of 50% ethanol extract of Agrimonia pilosa 10 g of a dried product of Agrimonia pilosa was immersed in 200 mL of a 50% ethanol aqueous solution at room temperature for 7 days for extraction. The obtained extract was filtered and then concentrated to dryness with an evaporator to obtain 1.0 g of a 50% ethanol extract of Agrimonia pilosa.
(製造例3)キンミズヒキのエタノール抽出物の調製
キンミズヒキの乾燥物10gを200mLのエタノールに室温で7日間浸漬し抽出を行った。得られた抽出液を濾過した後、エバポレーターで濃縮乾固してキンミズヒキのエタノール抽出物を0.2g得た。
(Production Example 3) Preparation of ethanol extract of Agrimonia pilosa 10 g of a dried product of Agrimonia pilosa was immersed in 200 mL of ethanol at room temperature for 7 days for extraction. The obtained extract was filtered and then concentrated to dryness with an evaporator to obtain 0.2 g of an ethanol extract of Agrimonia pilosa.
(製造例4)キンミズヒキの1,3−ブチレングリコール抽出物の調製
キンミズヒキの乾燥物10gを200mLの1,3−ブチレングリコールに室温で7日間浸漬し抽出を行った。得られた抽出液を濾過してキンミズヒキの1,3−ブチレングリコール抽出物を190g得た。
(Production Example 4) Preparation of 1,3-butylene glycol extract of Agrimonia pilosa 10 g of a dried product of Agrimonia pilosa was immersed in 200 mL of 1,3-butylene glycol at room temperature for 7 days for extraction. The obtained extract was filtered to obtain 190 g of 1,3-butylene glycol extract of Agrimonia pilosa.
(処方例1) 化粧水
処方 含有量(部)
1.キンミズヒキの熱水抽出物(製造例1) 2.0
2.1,3−ブチレングリコール 8.0
3.グリセリン 2.0
4.キサンタンガム 0.02
5.クエン酸 0.01
6.クエン酸ナトリウム 0.1
7.エタノール 5.0
8.パラオキシ安息香酸メチル 0.1
9.ポリオキシエチレン硬化ヒマシ油(40E.O.) 0.1
10.香料 適量
11.精製水にて全量を100とする
[製造方法]成分1〜6及び11と、成分7〜10をそれぞれ均一に溶解し、両者を混合し濾過して製品とする。
(Prescription example 1) Toner prescription content (part)
1. 1. Hot water extract of Agrimonia pilosa (Production Example 1) 2.0
2.1,3-butylene glycol 8.0
3. 3. Glycerin 2.0
4. Xanthan gum 0.02
5. Citric acid 0.01
6. Sodium citrate 0.1
7. Ethanol 5.0
8. Methyl paraoxybenzoate 0.1
9. Polyoxyethylene hydrogenated castor oil (40EO) 0.1
10. Appropriate amount of fragrance 11. [Manufacturing method] Ingredients 1 to 6 and 11 and components 7 to 10 are uniformly dissolved in purified water to make the total amount 100, and both are mixed and filtered to obtain a product.
(比較処方例1) 従来の化粧水
処方例1において、キンミズヒキの熱水抽出物を精製水に置き換えたものを、従来の化粧水とした。
(Comparative Formulation Example 1) Conventional Toner In Formulation Example 1, the hot water extract of Agrimonia pilosa was replaced with purified water, and the conventional lotion was used.
(処方例2) クリーム
処方 含有量(部)
1.キンミズヒキの50%エタノール抽出物(製造例2) 1.0
2.スクワラン 5.5
3.オリーブ油 3.0
4.ステアリン酸 2.0
5.ミツロウ 2.0
6.ミリスチン酸オクチルドデシル 3.5
7.ポリオキシエチレンセチルエーテル(20E.O.) 3.0
8.ベヘニルアルコール 1.5
9.モノステアリン酸グリセリン 2.5
10.香料 0.1
11.パラオキシ安息香酸メチル 0.2
12.1,3−ブチレングリコール 8.5
13.精製水にて全量を100とする
[製造方法]成分2〜9を加熱溶解して混合し、70℃に保ち油相とする。成分1及び11〜13を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分10を加え、さらに30℃まで冷却して製品とする。
(Prescription example 2) Cream prescription content (part)
1. 1. 50% ethanol extract of Agrimonia pilosa (Production Example 2) 1.0
2. Squalene 5.5
3. 3. Olive oil 3.0
4. Stearic acid 2.0
5. Beeswax 2.0
6. Octyldodecyl myristate 3.5
7. Polyoxyethylene cetyl ether (20EO) 3.0
8. Behenyl alcohol 1.5
9. Glycerin monostearate 2.5
10. Fragrance 0.1
11. Methyl paraoxybenzoate 0.2
12.1,3-butylene glycol 8.5
13. [Manufacturing method] Ingredients 2 to 9 having a total amount of 100 in purified water are melted by heating and mixed, and kept at 70 ° C. to prepare an oil phase. Ingredients 1 and 11 to 13 are heated and dissolved and mixed, and kept at 75 ° C. to prepare an aqueous phase. An aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring, component 10 is added at 45 ° C., and the mixture is further cooled to 30 ° C. to obtain a product.
(比較処方例2) 従来のクリーム
処方例2において、キンミズヒキの50%エタノール抽出物を精製水に置き換えたものを、従来のクリームとした。
(Comparative Formulation Example 2) Conventional Cream In Formulation Example 2, a cream obtained by replacing 50% ethanol extract of Agrimonia pilosa with purified water was used as a conventional cream.
(処方例3) 乳液
処方 含有量(部)
1.キンミズヒキのエタノール抽出物(製造例3) 0.01
2.スクワラン 5.0
3.オリーブ油 5.0
4.ホホバ油 5.0
5.セタノール 1.5
6.モノステアリン酸グリセリン 2.0
7.ポリオキシエチレンセチルエーテル(20E.O.) 3.0
8.ポリオキシエチレンソルビタンモノオレエート(20E.O.) 2.0
9.香料 0.1
10.プロピレングリコール 1.0
11.グリセリン 2.0
12.パラオキシ安息香酸メチル 0.2
13.精製水にて全量を100とする
[製造方法]成分1〜8を加熱溶解して混合し、70℃に保ち油相とする。成分10〜13を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分9を加え、さらに30℃まで冷却して製品とする。
(Prescription example 3) Emulsion prescription content (part)
1. 1. Ethanol extract of Agrimonia pilosa (Production Example 3) 0.01
2. Squalene 5.0
3. 3. Olive oil 5.0
4. Jojoba oil 5.0
5. Cetanol 1.5
6. Glycerin monostearate 2.0
7. Polyoxyethylene cetyl ether (20EO) 3.0
8. Polyoxyethylene sorbitan monooleate (20EO) 2.0
9. Fragrance 0.1
10. Propylene glycol 1.0
11. Glycerin 2.0
12. Methyl paraoxybenzoate 0.2
13. [Manufacturing method] Ingredients 1 to 8 having a total amount of 100 in purified water are melted by heating and mixed, and kept at 70 ° C. to prepare an oil phase. Ingredients 10 to 13 are heated and dissolved and mixed to prepare an aqueous phase at 75 ° C. An aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring, component 9 is added at 45 ° C., and the mixture is further cooled to 30 ° C. to obtain a product.
(処方例4) ゲル剤
処方 含有量(部)
1.キンミズヒキの1,3−ブチレングリコール抽出物(製造例4) 1.0
2.エタノール 5.0
3.パラオキシ安息香酸メチル 0.1
4.ポリオキシエチレン硬化ヒマシ油(60E.O.) 0.1
5.香料 適量
6.1,3−ブチレングリコール 5.0
7.グリセリン 5.0
8.キサンタンガム 0.1
9.カルボキシビニルポリマー 0.2
10.水酸化カリウム 0.2
11.精製水にて全量を100とする
[製造方法]成分2〜5と、成分1及び6〜11をそれぞれ均一に溶解し、両者を混合して製品とする。
(Prescription example 4) Gel preparation Prescription content (part)
1. 1. Agrimonia pilosa 1,3-butylene glycol extract (Production Example 4) 1.0
2. Ethanol 5.0
3. 3. Methyl paraoxybenzoate 0.1
4. Polyoxyethylene hydrogenated castor oil (60EO) 0.1
5. Appropriate amount of fragrance 6.1,3-butylene glycol 5.0
7. Glycerin 5.0
8. Xanthan gum 0.1
9. Carboxyvinyl polymer 0.2
10. Potassium hydroxide 0.2
11. [Manufacturing method] Ingredients 2 to 5 and components 1 and 6 to 11 having a total amount of 100 in purified water are uniformly dissolved, and the two are mixed to obtain a product.
(処方例5) パック
処方 含有量(部)
1.キンミズヒキの熱水抽出物(製造例1) 1.0
2.キンミズヒキの1,3−ブチレングリコール抽出物(製造例4) 5.0
3.ポリビニルアルコール 12.0
4.エタノール 5.0
5.1,3−ブチレングリコール 8.0
6.パラオキシ安息香酸メチル 0.2
7.ポリオキシエチレン硬化ヒマシ油(20E.O.) 0.5
8.クエン酸 0.1
9.クエン酸ナトリウム 0.3
10.香料 適量
11.精製水にて全量を100とする
[製造方法]成分1〜11を均一に溶解し製品とする。
(Prescription example 5) Pack prescription content (part)
1. 1. Hot water extract of Agrimonia pilosa (Production Example 1) 1.0
2. Agrimonia pilosa 1,3-butylene glycol extract (Production Example 4) 5.0
3. 3. Polyvinyl alcohol 12.0
4. Ethanol 5.0
5.1,3-butylene glycol 8.0
6. Methyl paraoxybenzoate 0.2
7. Polyoxyethylene hydrogenated castor oil (20EO) 0.5
8. Citric acid 0.1
9. Sodium citrate 0.3
10. Appropriate amount of fragrance 11. [Manufacturing method] Ingredients 1 to 11 having a total amount of 100 in purified water are uniformly dissolved to prepare a product.
(処方例6) ファンデーション
処方 含有量(部)
1.キンミズヒキの50%エタノール抽出物(製造例2) 1.0
2.ステアリン酸 2.4
3.ポリオキシエチレンソルビタンモノステアレート(20E.O.) 1.0
4.ポリオキシエチレンセチルエーテル(20E.O.) 2.0
5.セタノール 1.0
6.液状ラノリン 2.0
7.流動パラフィン 3.0
8.ミリスチン酸イソプロピル 6.5
9.カルボキシメチルセルロースナトリウム 0.1
10.ベントナイト 0.5
11.プロピレングリコール 4.0
12.トリエタノールアミン 1.1
13.パラオキシ安息香酸メチル 0.2
14.二酸化チタン 8.0
15.タルク 4.0
16.ベンガラ 1.0
17.黄酸化鉄 2.0
18.香料 適量
19.精製水にて全量を100とする
[製造方法]成分2〜8を加熱溶解し、80℃に保ち油相とする。成分19に成分9をよく膨潤させ、続いて、成分1及び10〜13を加えて均一に混合する。これに粉砕機で粉砕混合した成分14〜17を加え、ホモミキサーで撹拌し75℃に保ち水相とする。油相に水相をかき混ぜながら加え、乳化する。その後、冷却し、45℃で成分18を加え、かき混ぜながら30℃まで冷却して製品とする。
(Prescription example 6) Foundation prescription content (part)
1. 1. 50% ethanol extract of Agrimonia pilosa (Production Example 2) 1.0
2. Stearic acid 2.4
3. 3. Polyoxyethylene sorbitan monostearate (20EO) 1.0
4. Polyoxyethylene cetyl ether (20EO) 2.0
5. Cetanol 1.0
6. Liquid lanolin 2.0
7. Liquid paraffin 3.0
8. Isopropyl myristate 6.5
9. Sodium Carboxymethyl Cellulose 0.1
10. Bentonite 0.5
11. Propylene glycol 4.0
12. Triethanolamine 1.1
13. Methyl paraoxybenzoate 0.2
14. Titanium dioxide 8.0
15. Talc 4.0
16. Bengala 1.0
17. Yellow iron oxide 2.0
18. Appropriate amount of fragrance 19. [Manufacturing method] Ingredients 2 to 8 having a total amount of 100 in purified water are dissolved by heating and kept at 80 ° C. to prepare an oil phase. Ingredient 9 is well swollen with ingredient 19, followed by addition of ingredients 1 and 10-13 and mixed uniformly. Ingredients 14 to 17 pulverized and mixed by a pulverizer are added thereto, and the mixture is stirred with a homomixer and kept at 75 ° C. to prepare an aqueous phase. Add the aqueous phase to the oil phase while stirring to emulsify. Then, the mixture is cooled, component 18 is added at 45 ° C., and the product is cooled to 30 ° C. with stirring to obtain a product.
(処方例7) 浴用剤
処方 含有量(部)
1.キンミズヒキのエタノール抽出物(製造例3) 1.0
2.炭酸水素ナトリウム 50.0
3.黄色202号(1) 適量
4.香料 適量
5.硫酸ナトリウムにて全量を100とする
[製造方法]成分1〜5を均一に混合し製品とする。
(Prescription example 7) Prescription content for bath (part)
1. 1. Ethanol extract of Agrimonia pilosa (Production Example 3) 1.0
2. Sodium bicarbonate 50.0
3. 3. Yellow No. 202 (1) Appropriate amount 4. Appropriate amount of fragrance 5. [Manufacturing method] Ingredients 1 to 5 having a total amount of 100 with sodium sulfate are uniformly mixed to prepare a product.
(処方例8) 軟膏
処方 含有量(部)
1.キンミズヒキの熱水抽出物(製造例1) 5.0
2.キンミズヒキの1,3−ブチレングリコール抽出物(製造例4) 1.0
3.ポリオキシエチレンセチルエーテル(30E.O.) 2.0
4.モノステアリン酸グリセリン 10.0
5.流動パラフィン 5.0
6.セタノール 6.0
7.パラオキシ安息香酸メチル 0.1
8.プロピレングリコール 10.0
9.精製水にて全量を100とする
[製造方法]成分3〜6を加熱溶解して混合し、70℃に保ち油相とする。成分1、2及び7〜9を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら30℃まで冷却して製品とする。
(Prescription example 8) Ointment prescription content (part)
1. 1. Hot water extract of Agrimonia pilosa (Production Example 1) 5.0
2. Agrimonia pilosa 1,3-butylene glycol extract (Production Example 4) 1.0
3. 3. Polyoxyethylene cetyl ether (30EO) 2.0
4. Glycerin monostearate 10.0
5. Liquid paraffin 5.0
6. Cetanol 6.0
7. Methyl paraoxybenzoate 0.1
8. Propylene glycol 10.0
9. [Manufacturing method] Ingredients 3 to 6 having a total amount of 100 in purified water are melted by heating and mixed, and kept at 70 ° C. to prepare an oil phase. Ingredients 1, 2 and 7 to 9 are heated, dissolved and mixed, and kept at 75 ° C. to prepare an aqueous phase. An aqueous phase is added to the oil phase to emulsify, and the product is cooled to 30 ° C. with stirring.
(処方例9) 散剤
処方 含有量(部)
1.キンミズヒキの熱水抽出物(製造例1) 1.0
2.乾燥コーンスターチ 39.0
3.微結晶セルロース 60.0
[製造方法]成分1〜3を混合し、散剤とする。
(Prescription example 9) Powder prescription content (part)
1. 1. Hot water extract of Agrimonia pilosa (Production Example 1) 1.0
2. Dried cornstarch 39.0
3. 3. Microcrystalline Cellulose 60.0
[Manufacturing method] Ingredients 1 to 3 are mixed to prepare a powder.
(処方例10) 錠剤
処方 含有量(部)
1.キンミズヒキのエタノール抽出物(製造例3) 5.0
2.乾燥コーンスターチ 25.0
3.カルボキシメチルセルロースカルシウム 20.0
4.微結晶セルロース 40.0
5.ポリビニルピロリドン 7.0
6.タルク 3.0
[製造方法]成分1〜4を混合し、次いで成分5の水溶液を結合剤として加えて顆粒成型する。成型した顆粒に成分6を加えて打錠する。1錠0.52gとする。
(Prescription example 10) Tablet prescription content (part)
1. 1. Ethanol extract of Agrimonia pilosa (Production Example 3) 5.0
2. Dried cornstarch 25.0
3. 3. Carboxymethyl Cellulose Calcium 20.0
4. Microcrystalline Cellulose 40.0
5. Polyvinylpyrrolidone 7.0
6. Talc 3.0
[Manufacturing method] Ingredients 1 to 4 are mixed, and then an aqueous solution of ingredient 5 is added as a binder to form granules. Ingredient 6 is added to the molded granules and the mixture is locked. One tablet weighs 0.52 g.
(処方例11) 錠菓
処方 含有量(部)
1.キンミズヒキのエタノール抽出物(製造例3) 2.0
2.乾燥コーンスターチ 49.8
3.エリスリトール 40.0
4.クエン酸 5.0
5.ショ糖脂肪酸エステル 3.0
6.香料 0.1
7.精製水にて全量を100とする
[製造方法]成分1〜4及び7を混合し、顆粒成型する。成型した顆粒に成分5及び6を加えて打錠する。1粒1.0gとする。
(Prescription example 11) Tablet confectionery prescription content (part)
1. 1. Ethanol extract of Agrimonia pilosa (Production Example 3) 2.0
2. Dried cornstarch 49.8
3. 3. Erythritol 40.0
4. Citric acid 5.0
5. Sucrose fatty acid ester 3.0
6. Fragrance 0.1
7. Set the total amount to 100 with purified water
[Manufacturing method] Ingredients 1 to 4 and 7 are mixed and granulated. Ingredients 5 and 6 are added to the molded granules and the mixture is locked. One grain is 1.0 g.
(処方例12) 飲料
処方 含有量(部)
1.キンミズヒキの熱水抽出物(製造例1) 0.05
2.ステビア 0.05
3.リンゴ酸 5.0
4.香料 0.1
5.精製水にて全量を100とする
[製造方法]成分2及び3を少量の水に溶解する。次いで、成分1、4及び5を加えて混合する。
(Prescription example 12) Beverage prescription content (part)
1. 1. Hot water extract of Agrimonia pilosa (Production Example 1) 0.05
2. Stevia 0.05
3. 3. Malic acid 5.0
4. Fragrance 0.1
5. [Manufacturing method] Components 2 and 3 having a total amount of 100 in purified water are dissolved in a small amount of water. Then, ingredients 1, 4 and 5 are added and mixed.
次に、本発明の効果を詳細に説明するため、実験例を挙げる。 Next, in order to explain the effect of the present invention in detail, an experimental example will be given.
実験例1 細胞増殖促進試験
HaCaT細胞を、0.1%FBSを含むDMEM培養液にて、96wellプレートに1wellあたり5×103個播種し、各試料を添加した後、37℃、5%CO2条件下にて4日間培養した。細胞数の測定は、染色法により行った。すなわち、培養終了後、培養液を除き、メタノールを用いて細胞を固定した。続いて、0.1%メチレンブルーを加え、1時間細胞の染色を行った。乾燥させた後、0.1N HClを各wellに100μLずつ加えてよく撹拌させ、マイクロプレートリーダーを用いて650nmにおける吸光度を測定した。
Experimental Example 1 Cell proliferation promotion test HaCaT cells were seeded in DMEM culture medium containing 0.1% FBS in 5 × 10 3 cells per 1 well on a 96-well plate, and after adding each sample, the temperature was 37 ° C. and 5% CO. The cells were cultured under 2 conditions for 4 days. The number of cells was measured by the staining method. That is, after the completion of the culture, the culture solution was removed and the cells were fixed with methanol. Subsequently, 0.1% methylene blue was added, and the cells were stained for 1 hour. After drying, 100 μL of 0.1N HCl was added to each well and stirred well, and the absorbance at 650 nm was measured using a microplate reader.
これらの実験結果を表1に示した。その結果、本発明のキンミズヒキの熱水抽出物(製造例1)、50%エタノール抽出物(製造例2)及びエタノール抽出物(製造例3)は、優れた細胞増殖促進作用を示した。
実験例2 MMP−2 mRNA発現量の測定
ヒト線維芽細胞NB1RGBをφ60mm dishに1×105個播種し、コンフルエントになった時点で、終濃度が1μg/mLになるように試料を添加した。コントロールには、試料を希釈した溶媒を添加した。24時間培養後、総RNAの抽出を行った。細胞からの総RNAの抽出はRNAiso Plus(タカラバイオ)を用いて行い、総RNA量は分光光度計(NanoDrop)を用いて260nmにおける吸光度により求めた。mRNA発現量の測定は、細胞から抽出した総RNAを基にしてリアルタイムRT−PCR法により行った。リアルタイムRT−PCR法には、High Capacity RNA−to−cDNA Kit(アプライドバイオシステムズ)及びSYBR Select Master Mix(ライフテクノロジーズ)を用いた。すなわち、500ngの総RNAを逆転写反応後、PCR反応(95℃:15秒間、60℃:60秒間、40cycles)を行った。その他の操作は定められた方法に従い、MMP−2 mRNAの発現量を、内部標準であるβ−actin mRNAの発現量に対する割合として求めた。MMP−2発現率は、コントロールのMMP−2 mRNAの発現量に対する試料添加群のMMP−2 mRNAの発現量の比率として算出した。尚、各遺伝子の発現量の測定に使用したプライマーは次の通りである。
Experimental Example 2 Measurement of MMP-2 mRNA expression level Human fibroblasts NB1RGB were seeded in 1 × 10 5 pieces in a φ60 mm dish, and when they became confluent, samples were added so that the final concentration was 1 μg / mL. A solvent obtained by diluting the sample was added to the control. After culturing for 24 hours, total RNA was extracted. Extraction of total RNA from cells was performed using RNAiso Plus (Takara Bio), and the total amount of RNA was determined by absorbance at 260 nm using a spectrophotometer (NanoDrop). The mRNA expression level was measured by the real-time RT-PCR method based on the total RNA extracted from the cells. For the real-time RT-PCR method, High Capacity RNA-to- cDNA Kit (Applied Biosystems) and SYBR Select Master Mix (Life Technologies) were used. That is, after a reverse transcription reaction of 500 ng of total RNA, a PCR reaction (95 ° C: 15 seconds, 60 ° C: 60 seconds, 40 cycles) was performed. For other operations, the expression level of MMP-2 mRNA was determined as a ratio to the expression level of β-actin mRNA, which is an internal standard, according to a predetermined method. The MMP-2 expression rate was calculated as the ratio of the expression level of MMP-2 mRNA in the sample-added group to the expression level of the control MMP-2 mRNA. The primers used to measure the expression level of each gene are as follows.
MMP−2用のプライマーセット
CCGTCGCCCATCATCAA(配列番号1)
CTTCTGCATCTTCTTTAGTGTGTCCTT(配列番号2)
β−Actin用のプライマーセット
CACTCTTCCAGCCTTCCTTCC(配列番号3)
GTGTTGGCGTACAGGTCTTTG(配列番号4)
Primer set for MMP-2 CCGTCGCCCATCATCAA (SEQ ID NO: 1)
CTTTGCATCTTCTTTAGTGTGTCCTT (SEQ ID NO: 2)
Primer set for β-Actin CACTCTTCCAGCCTTCCTCC (SEQ ID NO: 3)
GTGTTGGGCGTACAGGTCTTG (SEQ ID NO: 4)
これらの実験結果を表2に示した。その結果、本発明のキンミズヒキの抽出物には、顕著なMMP−2発現抑制効果(MMP−2阻害効果)が認められた。さらに、キンミズヒキの50%エタノール抽出物(製造例2)のMMP−2発現抑制効果が特に高かった。
実験例5 使用試験
処方例1の化粧水及び比較処方例1の従来の化粧水を用いて、シワ、たるみがある5人(27〜65才)を対象に1ヶ月間の使用試験を行った。使用後、シワ、たるみの程度をアンケートにより判定した。
Experimental Example 5 Use test Using the lotion of Formulation Example 1 and the conventional lotion of Comparative Formulation 1, a one-month use test was conducted on 5 people (27-65 years old) with wrinkles and sagging. .. After use, the degree of wrinkles and sagging was judged by a questionnaire.
その結果、本発明の抽出物を含有する皮膚外用剤により、シワ、たるみが軽減した。尚、試験期間中、皮膚トラブルは一人もなく、安全性においても問題なかった。また、処方成分の劣化についても問題なかった。 As a result, wrinkles and sagging were alleviated by the external preparation for skin containing the extract of the present invention. During the test period, there were no skin problems and there was no problem in terms of safety. In addition, there was no problem with the deterioration of the prescription ingredients.
以上のことから、本発明のキンミズヒキの抽出物は、優れた細胞増殖促進効果及びMMP−2阻害作用を有し、安定性にも優れていた。よって、本発明のキンミズヒキの抽出物は、皮膚の老化といった美容分野だけでなく、老化による機能低下の抑制、ガンの予防、治療等といった医療分野にも利用でき、食品、化粧品、医薬部外品及び医薬品等への応用が期待される。 From the above, the extract of Agrimonia pilosa of the present invention had an excellent cell proliferation promoting effect and an MMP-2 inhibitory effect, and was also excellent in stability. Therefore, the extract of Kinmizuhiki of the present invention can be used not only in the beauty field such as skin aging but also in the medical field such as suppression of functional deterioration due to aging, cancer prevention, treatment, etc., and can be used for foods, cosmetics, quasi-drugs, etc. And is expected to be applied to pharmaceutical products.
Claims (6)
An internal product for the prevention and improvement of various diseases caused by an increase in MMP-2, which is characterized by containing an extract of Agrimonia pilosa.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019209598A JP2021080212A (en) | 2019-11-20 | 2019-11-20 | Cell proliferation promoter, mmp-2 inhibitor, topical skin preparation, pharmaceutical and internal preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019209598A JP2021080212A (en) | 2019-11-20 | 2019-11-20 | Cell proliferation promoter, mmp-2 inhibitor, topical skin preparation, pharmaceutical and internal preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021080212A true JP2021080212A (en) | 2021-05-27 |
Family
ID=75964092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019209598A Pending JP2021080212A (en) | 2019-11-20 | 2019-11-20 | Cell proliferation promoter, mmp-2 inhibitor, topical skin preparation, pharmaceutical and internal preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2021080212A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010195731A (en) * | 2009-02-26 | 2010-09-09 | Kao Corp | Dopa oxidase activity inhibitor and beautifying agent |
-
2019
- 2019-11-20 JP JP2019209598A patent/JP2021080212A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010195731A (en) * | 2009-02-26 | 2010-09-09 | Kao Corp | Dopa oxidase activity inhibitor and beautifying agent |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6437342B2 (en) | A skin external preparation or an internal preparation containing an extract of echinacea cultivated by irradiating light having a specific wavelength range. | |
JP6803110B2 (en) | External and internal skin preparations containing an extract of nasturtium cultivated by irradiating light with a specific wavelength range | |
JP7278577B2 (en) | External skin preparation or internal preparation | |
JP6247847B2 (en) | Skin wrinkle formation preventive / improving agent, hyaluronic acid production promoter, collagen production promoter and MMP inhibitor | |
JP5138262B2 (en) | Topical skin preparation | |
JP7148115B2 (en) | Collagen production promoter, MMP inhibitor, melanogenesis inhibitor, cell proliferation promoter, antioxidant, wrinkle improving agent, pharmaceutical or food composition | |
JP6779627B2 (en) | How to make callus for Queen of the Night, and external and internal skin preparations containing the extract as an active ingredient | |
JP6731241B2 (en) | Skin external and internal preparations using herb sprout | |
JP2005023021A (en) | Elastase inhibitor | |
JP2021080212A (en) | Cell proliferation promoter, mmp-2 inhibitor, topical skin preparation, pharmaceutical and internal preparation | |
JP2023077751A (en) | Collagen production promoter, MMP inhibitor, cell proliferation promoter and internal agent | |
JP6281761B2 (en) | External preparation or internal preparation containing Hidakami Sebaya extract | |
JP2022191664A (en) | Collagen production promoter, mmp-2 inhibitor, cell growth promoter and internal agent | |
JP7433628B2 (en) | Skin external preparations and internal preparations | |
JP2022010923A (en) | Collagen production promoter, cell growth promoter, and melanin production inhibitor | |
JP7389465B2 (en) | Melanin production inhibitor, collagen production promoter and antioxidant | |
JP7316647B2 (en) | Cathepsin V activity promoter and GATA-3 production inhibitor | |
JP7278564B2 (en) | Hyaluronic Acid Production Promoter, Collagen Production Promoter, MMP Inhibitor, Wrinkle Improving Agent, Pharmaceutical or Food Composition | |
JP5690149B2 (en) | External preparation or internal preparation | |
JP7454209B2 (en) | Capillary dilation inhibitor | |
JP2022034789A (en) | External and internal skin agents | |
JP2023007747A (en) | Mmp inhibitors, enhancers for hyaluronic acid production and internal preparations | |
JP2022024329A (en) | Melanin production inhibitor, collagen production promoter, hyaluronic acid production promoter, mmp-2 inhibitor, and internal agent | |
JP2022111768A (en) | External and internal agents for skin | |
JP2022189261A (en) | Collagen production promoter, MMP inhibitor, hyaluronic acid production promoter and internal agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220914 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230712 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230801 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230926 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231114 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240105 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240402 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240627 |